A study published in the New England Journal of Medicine examined the survival of patients with advanced non-small cell lung cancer (NSCLC) with an EGFR mutation treated with a combination of osimertinib and chemotherapy. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that has better efficacy and penetrates the central nervous system (CNS) better than previous generations of drugs. The FLAURA 2 study enrolled 557 patients with EGFR mutations (exon 19 deletion or exon 21 mutation) who received osimertinib with chemotherapy or osimertinib alone. Combination therapy demonstrated improved overall survival and CNS disease control compared with osimertinib monotherapy. Osimertinib alone is the standard of care for first-line treatment in EGFR-mutated NSCLC, based on previous studies showing a 37% reduction in the risk of death over older EGFR-TKIs. Combination with chemotherapy has been shown to be a safe and effective option in disease progression or in later lines of treatment. This combination thus represents a new therapeutic approach for patients with advanced EGFR-mutated NSCLC who need additional treatment after failure of monotherapy[1][3][8].